TTD Drug ID: DCL000005

Drug Information
Name	Marimastat
Synonyms	15039-60-8; Butanediamide, N4-(2,2-dimethyl-1-((methylamino)carbonyl)propyl)-N1,2-dihydroxy-3-(2-methylpropyl)-, (2S-(N4(R*),2R*,3S*))-; D03795; (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; Marimastat [USAN]; CHEBI:50662; BB-2516; Butanediamide, N4-((1S)-2,2-dimethyl-1-((methylamino)carbonyl)propyl)-N1,2-dihydroxy-3-(2-methylpropyl)-, (2S,3R)-; UNII-D5EQV23TDS; 154039-60-8; DB00786; CHEMBL279785; Butanediamide, N(sup 4)-(2,2-dimethyl-1-((methylamino)carbonyl)propyl)-N(sup 1),2-dihydroxy-3-(2-methylpropyl)-, (2S-(N(sup 4)(R*),2R*,3S*))-; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide; AC1L3O2N; C15H29N3O5; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; CID119031; Marimastat; C100342; LS-45634; BB 2516; Marimastat (USAN/INN); (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid
Company	British Biotech plc / Schering-Plough
Indication	Pancreatic Cancer, Lung Cancer			Discontinued in Phase III    [1]
Structure	Click to save drug structure in 3D MOL format Click to save drug structure in 2D MOL format
Therapeutic Class	Antineoplastic Agents
CAS Number	CAS 154039-60-8
PubChem Compound ID	CID 119031.
PubChem Substance ID	SID 583701.
ClinicalTrials.gov	NCT00002911;
Target	MMP-1			Inhibitor	[2][3][4][5]
	MMP-1			Multitarget	[2][3][4][5]
	MMP-2			Inhibitor	[2][3][4][5]
	MMP-2			Multitarget	[2][3][4][5]
	MMP-7			Inhibitor	[2][3][4][5]
	MMP-7			Multitarget	[2][3][4][5]
Ref 1	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. To Reference
Ref 2	Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. Eur J Pharmacol. 2007 Mar 15;559(1):75-81. Epub 2006 Dec 12. To Reference
Ref 3	Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Med Sci Monit. 2009 Feb;15(2):RA32-40. To Reference
Ref 4	Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther. 1997;75(1):69-75. To Reference
Ref 5	16498445 To Reference

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.